Dova Pharmaceuticals to Present at the UBS Global Healthcare Conference

Dova Pharmaceuticals to Present at the UBS Global Healthcare Conference

May 20, 2019

DURHAM, N.C., May 20, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 2:00 p.m. ET in New York, NY. 

A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.

About Dova Pharmaceuticals, Inc.

Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s proprietary pipeline includes one commercial product, DOPTELET®, for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Contacts

Mark W. Hahn
(919) 338-7936
mhahn@dova.com

Westwicke
John Woolford
(443) 213-0506
john.woolford@westwicke.com

 

dovalogo.png

Source: Dova Pharmaceuticals, Inc.